Hydantoin derivative compounds, methods of use and methods of treatment

Abstract

The present disclosure provides compositions including a hydantoin derivative compound, pharmaceutical compositions including a hydantoin derivative compound, methods of treatment of a condition (e.g., bacterial infection) or disease, methods of treatment using compositions or pharmaceutical compositions, and the like.

We claim at least the following: 
     
       1. A hydantoin derivative compound having the following structure: 
       
         
           
           
               
               
           
         
         wherein D 1  is a hydantoin core, D 2  is a membrane interacting domain, R 1  is a hydrophobic group, R 2  is selected from the group consisting of a NH 2  group, an aminobutyl group, an aminopentyl group, an aminohexyl group, and an aminopropyl group, and X is a lipid tail. 
       
     
     
       2. The hydantoin derivative compound of  claim 1 , wherein the lipid tail X is a 5 to 15 carbon alkyl group. 
     
     
       3. The hydantoin derivative compound of  claim 2 , wherein the lipid tail X is selected from a 10 to 12 carbon linear alkyl group. 
     
     
       4. The hydantoin derivative compound of  claim 2 , wherein R 1  is an alkyl group, aryl group, or a cycloalkyl group, each of which is substituted or unsubstituted. 
     
     
       5. The hydantoin derivative compound of  claim 4 , wherein R 1  is an ethyl group, a phenyl group, meta-chlorobenzyl, indole, biphenyl, terphenyl, or 6-chloro indole. 
     
     
       6. The hydantoin derivative compound of  claim 2 , wherein the hydantoin derivative compound has the following structure: 
       
         
           
           
               
               
           
         
       
     
     
       7. A pharmaceutical composition comprising:
 a hydantoin derivative compound, or a pharmaceutically acceptable salt of the hydantoin derivative compound, having the following structure: 
 
       
         
           
           
               
               
           
         
         
           wherein D 1  is a hydantoin core, D 2  is a membrane interacting domain, R 1  is a hydrophobic group, R 2  is selected from the group consisting of a NH 2  group, an aminobutyl group, an aminopentyl group, an aminohexyl group, and an aminopropyl group, and X is a lipid tail; 
         
         and a pharmaceutically acceptable carrier. 
       
     
     
       8. The pharmaceutical composition of  claim 7 , wherein the lipid tail X is a 5 to 15 carbon alkyl group. 
     
     
       9. The pharmaceutical composition of  claim 7 , wherein the lipid tail X is selected from a 10 to 12 carbon linear alkyl group. 
     
     
       10. The pharmaceutical composition of  claim 7 , wherein R 1  is an alkyl group, aryl group, or a cycloalkyl group, each of which is substituted or unsubstituted. 
     
     
       11. The pharmaceutical composition of  claim 10 , wherein R 1  is an ethyl group, a phenyl group, meta-chlorobenzyl, indole, biphenyl, terphenyl, or 6-chloro indole. 
     
     
       12. The pharmaceutical composition of  claim 7 , wherein the hydantoin derivative compound has the following structure: